Stockscreener 앱 받기
2.02
5.61%
-0.12
시간 외 거래:
2.00
-0.02
-0.99%
전일 마감가:
$2.14
열려 있는:
$2.08
하루 거래량:
73,274
Relative Volume:
1.43
시가총액:
$24.35M
수익:
$52.16M
순이익/손실:
$-48.60M
주가수익비율:
-2.2198
EPS:
-0.91
순현금흐름:
$-77.48M
1주 성능:
-5.16%
1개월 성능:
-25.74%
6개월 성능:
-69.25%
1년 성능:
-64.25%
1일 변동 폭
$2.00
$2.14
1주일 범위
$1.9601
$2.27
52주 변동 폭
$1.88
$11.30
Hookipa Pharma Inc Stock (HOOK) Company Profile
명칭
Hookipa Pharma Inc
전화
0114318906360
주소
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
HOOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HOOK
Hookipa Pharma Inc
|
2.02 | 24.35M | 52.16M | -48.60M | -77.48M | -4.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-12-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-11-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-08 | 개시 | Morgan Stanley | Overweight |
| 2020-11-03 | 개시 | Truist | Buy |
| 2020-10-26 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-19 | 재개 | H.C. Wainwright | Buy |
| 2019-09-27 | 개시 | H.C. Wainwright | Buy |
| 2019-05-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-13 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Hookipa Pharma Inc 주식(HOOK)의 최신 뉴스
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26% - Simply Wall St
RBC downgrades HOOKIPA Pharma stock to Sector Perform as restructuring resets pipeline to preclinical - Investing.com
HOOKIPA Pharma's SWOT analysis: stock faces challenges amid pipeline shifts By Investing.com - Investing.com South Africa
Fmr LLC Has $1.47 Million Holdings in Hookipa Pharma Inc (NASDAQ:HOOK) - Defense World
HOOKIPA Pharma's SWOT analysis: stock faces challenges amid pipeline shifts - Investing.com
Hookipa Pharma stock hits 52-week low at $2.07 amid market challenges - Investing.com
HOOK (HOOKIPA Pharma) COGS-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) GF Value Rank : 2 (As of Nov. 25, 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) Debt-to-Equity : 0.04 (As of Sep. 2024) - GuruFocus.com
JMP Securities Has Lowered Expectations for Hookipa Pharma (NASDAQ:HOOK) Stock Price - Defense World
Hookipa Pharma price target lowered to $7 from $24 at JMP Securities - Yahoo Finance
Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program - Yahoo Finance
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges - Investing.com Canada
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges By Investing.com - Investing.com South Africa
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky - Simply Wall St
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
HOOKIPA Pharma stock target lowered, maintains outlook on strategic direction - Investing.com
RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target - Quantisnow
HOOKIPA Pharma Inc (HOOK) Quarterly 10-Q Report - Quartzy
Hookipa Pharma stock hits 52-week low at $3.4 amid market challenges - Investing.com Australia
Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes - TipRanks
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates - The Bakersfield Californian
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker - The Manila Times
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker - GlobeNewswire
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market By Investing.com - Investing.com UK
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - Quantisnow
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline - GlobeNewswire
HOOKIPA commences HPV16+ cancer adjuvant care trial - Investing.com India
HOOKIPA commences HPV16+ cancer adjuvant care trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - The Manila Times
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator - The Bakersfield Californian
HOOKIPA Pharma Doses First Patients with Eseba-vec as - GlobeNewswire
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges By Investing.com - Investing.com South Africa
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges - Investing.com
Hookipa Pharma stock hits 52-week low at $4.06 amid market challenges - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in cancer immunotherapy - Investing.com
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
HOOKIPA presents KRAS cancer treatment data By Investing.com - Investing.com South Africa
HOOKIPA presents KRAS cancer treatment data - Investing.com India
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset - Marketscreener.com
Hookipa Pharma Inc (HOOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):